Skip to main content
. Author manuscript; available in PMC: 2019 Feb 15.
Published in final edited form as: Cancer Res. 2017 Dec 19;78(4):1044–1057. doi: 10.1158/0008-5472.CAN-17-1904

Figure 2. Identified synergy enhancers and synergy suppressors.

Figure 2

Genome wide CRISPR screen dissects synergistic effect of THZ1. A), B) Scatter plots for synergy enhancer genes (A) or synergy suppressor genes (B). Horizontal axis indicates average log 2 fold change (LFC) from early time point sample after erlotinib treatment. Vertical axis indicates delta log 2 fold change between erlotinib treatment and combination treatment. Tables indicate the most enriched (FDR <0.25) genes ranked by STARS algorithm for synergy enhancer genes (A) or synergy suppressor genes (B). GO analysis was performed with the enriched synergy suppressor genes (B).